Cargando…

Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine

Background: Subjects with previous COVID-19 have augmented post-vaccination responses. However, the antibody response in COVID-naïve subjects from Southeast Asia is not well known. Methods: 77 COVID-naïve vaccinees were tested with a full antibody panel [spike antibodies (total (T-Ab), IgG, IgM) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Chin-Shern, Phua, Soon Kieng, Liang, Ya-Li, Oh, Helen May-Lin, Aw, Tar-Choon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622758/
https://www.ncbi.nlm.nih.gov/pubmed/34835172
http://dx.doi.org/10.3390/vaccines9111241
_version_ 1784605769071591424
author Lau, Chin-Shern
Phua, Soon Kieng
Liang, Ya-Li
Oh, Helen May-Lin
Aw, Tar-Choon
author_facet Lau, Chin-Shern
Phua, Soon Kieng
Liang, Ya-Li
Oh, Helen May-Lin
Aw, Tar-Choon
author_sort Lau, Chin-Shern
collection PubMed
description Background: Subjects with previous COVID-19 have augmented post-vaccination responses. However, the antibody response in COVID-naïve subjects from Southeast Asia is not well known. Methods: 77 COVID-naïve vaccinees were tested with a full antibody panel [spike antibodies (total (T-Ab), IgG, IgM) and neutralizing antibodies (N-Ab)] pre-vaccination, 10 days after dose 1, and 20/40/60/90/120/150/180 days after dose 2. Results: 10 days after dose 1, 67.6% (48/71)/69.0% (49/71) were T-Ab/IgG positive; only 15.5% (11/71)/14.1% (10/71) were N-Ab/IgM positive. While all (100%) subjects had brisk T-Ab, IgG and N-Ab antibody responses 20 days after complete vaccination, only 79.1% (53/67) were IgM positive. At 180 days (n = 8), T-Ab/IgG/N-Ab were still reactive (lowest T-Ab 186 U/mL, IgG 617 AU/mL, N-Ab 0.39 µg/mL), but IgM was negative in all samples. Spike antibody thresholds of T-Ab 74.1 U/mL (r = 0.95) and IgG 916 AU/mL (r = 0.95) corresponded to N-Ab reactivity (>0.3 µg/mL). Non-linear regression analysis showed that N-Ab would decrease to 0.3 µg/mL by 241 days, whereas T-Ab/IgG would need 470/163 days to reach titers of T-Ab/IgG associated with a N-Ab 0.3 µg/mL (76.4 U/mL and 916 AU/mL respectively). Conclusions: The antibody responses of T-Ab, IgG and N-Ab remain high and durable even at 180 days. N-Ab titers are expected to remain reactive up to 241 days post-vaccination.
format Online
Article
Text
id pubmed-8622758
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86227582021-11-27 Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine Lau, Chin-Shern Phua, Soon Kieng Liang, Ya-Li Oh, Helen May-Lin Aw, Tar-Choon Vaccines (Basel) Article Background: Subjects with previous COVID-19 have augmented post-vaccination responses. However, the antibody response in COVID-naïve subjects from Southeast Asia is not well known. Methods: 77 COVID-naïve vaccinees were tested with a full antibody panel [spike antibodies (total (T-Ab), IgG, IgM) and neutralizing antibodies (N-Ab)] pre-vaccination, 10 days after dose 1, and 20/40/60/90/120/150/180 days after dose 2. Results: 10 days after dose 1, 67.6% (48/71)/69.0% (49/71) were T-Ab/IgG positive; only 15.5% (11/71)/14.1% (10/71) were N-Ab/IgM positive. While all (100%) subjects had brisk T-Ab, IgG and N-Ab antibody responses 20 days after complete vaccination, only 79.1% (53/67) were IgM positive. At 180 days (n = 8), T-Ab/IgG/N-Ab were still reactive (lowest T-Ab 186 U/mL, IgG 617 AU/mL, N-Ab 0.39 µg/mL), but IgM was negative in all samples. Spike antibody thresholds of T-Ab 74.1 U/mL (r = 0.95) and IgG 916 AU/mL (r = 0.95) corresponded to N-Ab reactivity (>0.3 µg/mL). Non-linear regression analysis showed that N-Ab would decrease to 0.3 µg/mL by 241 days, whereas T-Ab/IgG would need 470/163 days to reach titers of T-Ab/IgG associated with a N-Ab 0.3 µg/mL (76.4 U/mL and 916 AU/mL respectively). Conclusions: The antibody responses of T-Ab, IgG and N-Ab remain high and durable even at 180 days. N-Ab titers are expected to remain reactive up to 241 days post-vaccination. MDPI 2021-10-25 /pmc/articles/PMC8622758/ /pubmed/34835172 http://dx.doi.org/10.3390/vaccines9111241 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lau, Chin-Shern
Phua, Soon Kieng
Liang, Ya-Li
Oh, Helen May-Lin
Aw, Tar-Choon
Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
title Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
title_full Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
title_fullStr Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
title_full_unstemmed Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
title_short Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
title_sort robust sars-cov-2 antibody responses in asian covid-naïve subjects 180 days after two doses of bnt162b2 mrna covid-19 vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622758/
https://www.ncbi.nlm.nih.gov/pubmed/34835172
http://dx.doi.org/10.3390/vaccines9111241
work_keys_str_mv AT lauchinshern robustsarscov2antibodyresponsesinasiancovidnaivesubjects180daysaftertwodosesofbnt162b2mrnacovid19vaccine
AT phuasoonkieng robustsarscov2antibodyresponsesinasiancovidnaivesubjects180daysaftertwodosesofbnt162b2mrnacovid19vaccine
AT liangyali robustsarscov2antibodyresponsesinasiancovidnaivesubjects180daysaftertwodosesofbnt162b2mrnacovid19vaccine
AT ohhelenmaylin robustsarscov2antibodyresponsesinasiancovidnaivesubjects180daysaftertwodosesofbnt162b2mrnacovid19vaccine
AT awtarchoon robustsarscov2antibodyresponsesinasiancovidnaivesubjects180daysaftertwodosesofbnt162b2mrnacovid19vaccine